Opicinumab
Opicinumab (BIIB033) is a monoclonal antibody against LINGO-1 and has potential application in acute optic neuritis and relapse multiple sclerosis[1][2].
Product Specifications
CAS Number
1422268-07-2
Product Name Alternative
BIIB033
UNSPSC
12352203
Target
Others
Type
Inhibitory Antibodies
Related Pathways
Others
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/opicinumab.html
Purity
99.5
Solubility
10 mM in DMSO
Smiles
[Opicinumab]
Molecular Weight
(145.2 kDa)
References & Citations
[1]Cadavid D, et al. Safety and efficacy of opicinumab in acute optic neuritis (RENEW) : a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2017 Mar;16 (3) :189-199.|[2]Cadavid D, et al. Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY) : a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2019 Sep;18 (9) :845-856.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
MBS1270613-01 0.01 mg Plasmid + 0.2 mL Glycerol-Stock
TMEM144 cDNA Clone
Sign In for Pricing
View Details